Bristlecone Advisors LLC Has $2.40 Million Position in Zoetis Inc. $ZTS

Bristlecone Advisors LLC reduced its holdings in Zoetis Inc. (NYSE:ZTS) by 3.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 15,362 shares of the company’s stock after selling 539 shares during the quarter. Bristlecone Advisors LLC’s holdings in Zoetis were worth $2,396,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Nova Wealth Management Inc. acquired a new stake in Zoetis during the first quarter worth about $25,000. 1248 Management LLC acquired a new stake in Zoetis during the first quarter worth about $27,000. Saudi Central Bank acquired a new stake in Zoetis during the first quarter worth about $29,000. Cornerstone Planning Group LLC grew its position in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after buying an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC grew its position in Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after buying an additional 131 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ZTS shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Argus reissued a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. UBS Group decreased their target price on Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research report on Monday, October 20th. Finally, Piper Sandler raised their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $195.00.

Zoetis Stock Down 1.3%

NYSE ZTS opened at $145.62 on Wednesday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock’s 50 day moving average is $147.88 and its two-hundred day moving average is $153.51. The company has a market capitalization of $64.53 billion, a price-to-earnings ratio of 25.06, a PEG ratio of 2.37 and a beta of 0.90. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $184.40.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is presently 34.42%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.